Current and Emerging BCMAxCD3 Bispecifics

In the past 10 years, bispecific antibodies have revolutionized the treatment algorithm for relapsed or refractory multiple myeloma. To date, there are 3 BCMA-directed bispecific antibodies that treat RRMM: teclistamab, elranatamab, and linvoseltamab. Therapy sequence and distinctions among agents are a current clinical conundrum. Ongoing research focuses on drug differences, order of agents, managing resistance, and mitigating adverse effects to improve outcomes in multiple myeloma.